Cel "JThe JEM project aims to bring to the healthcare and medical device markets the first subcutaneous enclosed implantable device attached directly to a vein, fistula or graft. The JEM is based on a patented design that greatly improves repetitive vascular access techniques and provides safer, more accurate and effective results.The JEM provides the following advantages:• It is based on the European Gold Standard ""buttonhole technique"" for vascular access.• It greatly reduces costs by reducing the need for fistula repair & replacement.• It enables repetitive puncturing at the same spot by less-trained clinicians. • Its 6-year lifespan, 3 times the average fistula lifespan, reduces mortality & morbidity.• Its specially designed needle prevents back wall perforation and hematomas.• It will allow for a larger gauge needle thereby potentially increasing blood flow and lowering the risk of hemolysis.• It can be made to use a unique blunt needle that is sold by Access for Life, causing less pain to the patients ensuring easier and safer home hemodialysis.JEM devices from Access for Life are designed for all patients in need of repetitive vascular access: hemodialysis patients, oncology patients receiving chemotherapy, patients with blood disorders, patients requiring regular medications or blood transfusions, burn victims, pediatric patients and patients with digestive disorders.Due to its longevity, JEM eliminates three of the four operations dialysis patients usually undergo in a 6-year period. This will save healthcare systems about 5,8K € per dialysis patient. Multiplied by the growing number of patients, a conservative estimate of potential savings is over 200M € a year.Through the JEM project, we seek to position our company as the leading player in medical devices for repetitive vascular access, a market that is continually growing. Access for Life offers universal solutions for a wide range of clinical applications that require vascular access." Dziedzina nauki medical and health sciencesclinical medicineangiologyvascular diseasesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinenephrologymedical and health sciencesclinical medicineoncologymedical and health sciencesclinical medicinehematology Program(-y) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Temat(-y) SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2016-2017 System finansowania SME-1 - SME instrument phase 1 Koordynator ACCESS FOR LIFE Wkład UE netto € 50 000,00 Adres 11 HAGRA STREET 4252008 NETANYA Izrael Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
